Similarly, chronic treatment with a different long-acting GLP-1 analog, liraglutide, improves deficits in spatial memory observed in a rat model of central streptozotocin (STZ)-induced neurotoxicity and diabetes (Palleria et al., 2017), an outcome also observed following exenatide treatment (Chen et al., 2012). Here, GLP1R is linked to diabetes mellitus.